4. Entresto

There is great hope that Entresto might be effective in HFpEF, which accounts for around half of all heart failure cases. As it turned out, the PARAGON-HF trial of Entresto in HFpEF proved to be something of a disappointment, missing its main goal of reducing deaths and emergency hospitalizations.